Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Increase in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 11,893,654 shares, an increase of 24.0% from the December 15th total of 9,589,100 shares. Based on an average daily trading volume, of 3,196,474 shares, the days-to-cover ratio is presently 3.7 days. Currently, 11.7% of the company’s stock are sold short. Currently, 11.7% of the company’s stock are sold short. Based on an average daily trading volume, of 3,196,474 shares, the days-to-cover ratio is presently 3.7 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Canaccord Genuity Group restated a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a report on Friday, December 19th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a research note on Tuesday, December 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Fractyl Health has a consensus rating of “Moderate Buy” and an average target price of $7.40.

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS traded down $0.06 during midday trading on Monday, hitting $1.91. 2,523,545 shares of the stock were exchanged, compared to its average volume of 2,453,125. The business’s fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $1.51. Fractyl Health has a 52-week low of $0.83 and a 52-week high of $3.03. The company has a market capitalization of $261.75 million, a PE ratio of -0.83 and a beta of 1.62.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, equities analysts anticipate that Fractyl Health will post -1.61 EPS for the current year.

Institutional Trading of Fractyl Health

A number of institutional investors and hedge funds have recently made changes to their positions in GUTS. Nantahala Capital Management LLC bought a new position in shares of Fractyl Health in the 3rd quarter valued at approximately $19,298,000. Alyeska Investment Group L.P. bought a new stake in shares of Fractyl Health in the third quarter valued at approximately $8,981,000. Rosalind Advisors Inc. bought a new stake in Fractyl Health in the 3rd quarter valued at $7,950,000. Woodline Partners LP lifted its stake in shares of Fractyl Health by 821.1% in the third quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after buying an additional 4,908,693 shares during the period. Finally, General Catalyst Group Management LLC bought a new position in Fractyl Health during the second quarter valued at about $7,912,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.